Lotte S. Spekhorst
Utrecht, UT, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
Type 2 Immune-Dominant Endotype Is Not Associated With Increased Responsiveness to Dupilumab Treatment in Adult Atopic Dermatitis Patients.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: July 03, 2024
Dupilumab-Associated Lymphoid Reactions in Patients With Atopic Dermatitis.
Journal: JAMA dermatology
Published: October 18, 2023
Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: Up to 5-year results from the daily practice BioDay registry.
Journal: Journal of the American Academy of Dermatology
Published: July 26, 2023
Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis.
Journal: The Journal of allergy and clinical immunology
Published: July 21, 2023
The positive effect of dupilumab on comorbid asthma in patients with atopic dermatitis.
Journal: Clinical and translational allergy
Published: January 27, 2023
Muscle and joint pain during dupilumab treatment for atopic dermatitis: Lack of association with antinuclear antibodies.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: December 21, 2022
Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry.
Journal: The British journal of dermatology
Published: December 19, 2022
Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry.
Journal: Acta dermato-venereologica
Published: November 24, 2022
Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry.
Journal: JAMA dermatology
Published: November 02, 2022
Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry.
Journal: Acta dermato-venereologica
Published: October 25, 2022
Last Updated: 09/26/2026